Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people familiar with the matter.
The biotechnology company is set to pay $1.25 billion upfront in cash to Star's venture capital backers and a further $750 million based on certain performance milestones being met, the report said.
Reuters could not immediately verify the report.
(Reporting by Preetika Parashuraman in BengaluruEditing by Tomasz Janowski)
Copyright Reuters or USA Today Network via Reuters Connect